UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

April 30, 2009


ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

0-20852

16-1387013

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 


2000 Technology Parkway, Newark, New York       14513

(Address of principal executive offices)            (Zip Code)


(315) 332-7100
(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02. Results of Operations and Financial Condition.

Ultralife Corporation (the “Company”) reported revenue of $39.8 million for its first quarter ended March 29, 2009, a decrease of $9.8 million, or 20%, from the $49.6 million in revenue reported for the comparable quarter of 2008.  The Company reported an operating loss of $2.3 million in the first quarter of 2009, compared with operating income of $2.4 million in the same period a year ago.   

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Item 9.01. Financial Statements, Pro Forma Financials and Exhibits.

  (a)   Exhibits.
 
99.1 Press Release dated April 30, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ULTRALIFE CORPORATION

Dated:

 April 30, 2009

By:

 

/s/Robert W. Fishback

Vice President of Finance & CFO


INDEX TO EXHIBITS

(99)   Additional Exhibits
 

99.1      Press Release dated April 30, 2009.